Saturday, 5 September 2026European Markets

ATENOR Stock 19.81% Up On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with ATENOR (ATEB.BR) rising 19.81% to €12.40 on Tuesday, following the last session's upward trend. BEL 20 jumped 1.75% to €3,540.94, following the last session's downward trend on what was an all-around positive trend exchanging session today.

About ATENOR

Atenor SA, a real estate development company, invests in large-scale real estate projects in Belgium, Luxembourg, the Netherlands, France, Germany, Portugal, Poland, Hungary, the United Kingdom, and Romania. The company develops real estate projects, such as offices and residential buildings. Atenor SA was founded in 1910 and is headquartered in La Hulpe, Belgium.

Earnings Per Share

As for profitability, ATENOR has a trailing twelve months EPS of €-9.45.

Volume

Today's last reported volume for ATENOR is 15165 which is 163.69% above its average volume of 5751.

Volatility

ATENOR's last week, last month's, and last quarter's current intraday variation average was a positive 2.25%, a negative 2.68%, and a positive 3.23%.

ATENOR's highest amplitude of average volatility was 5.14% (last week), 5.19% (last month), and 3.23% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ATENOR's stock is considered to be oversold (<=20).

More news about ATENOR (ATEB.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com